CROMA-PHARMA
31.5.2021 17:12:04 CEST | Business Wire | Press release
Croma-Pharma (Croma) is opening a new chapter and expanding its product portfolio to meet the growing needs of its customers. With the innovative skincare brand Croma farewell™, the company is specifically addressing the desire of consumers for natural, effective and individual skincare and building upon its many years of experience in the production of hyaluronic acid. The name says it all: consumers say goodbye to their facial skin problems and hello to their new selves when using Croma farewell™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210531005179/en/
The Austrian produced brand will initially launch in all key markets with facial serums for five specific skin types.
High-quality care for specific skin conditions based on hyaluronic acid
Genetics, external factors and psychological influences can have a decisive impact on an individual’s skin condition and lead to various problems. Croma viewed this situation as an opportunity to develop a high-quality facial care line for specific skin needs: Croma farewell™.
The Croma farewell™ cosmetic portfolio of five different facial serums unites carefully selected ingredients with years of experience in the pharmaceutical and aesthetic field. Based on this expertise, all formulations contain a blend of both high and low molecular weight hyaluronic acid – an antioxidant that moisturizes and hydrates the skin, improves elasticity and smoothes and plumps the skin’s appearance to reduce fine lines and wrinkles.
All ingredients incorporated into the serums are carefully selected and based on scientific data to achieve the most effective results.
"With the launch of Croma farewell™, we are strengthening our focus on personalized skincare innovation, drawing on our many years of expertise as well as the latest scientific findings. Croma farewell™ meets the high standard of our medical products and perfectly complements our existing portfolio", explains Managing Director, Andreas Prinz.
Concentrated efficacy: 5 serums for 5 common facial skin conditions
-
farewell irritated skin: Target-specific face serum for irritated, sensitive skin with Hyaluronic Acid, Madecassoside, Niacinamide and D-Panthenol to sooth irritations, reduce skin redness and strengthen the skin barrier.
Perfume free. 30 ml.
-
farewell puffy eyes: A face serum, especially designed for the eye contour, to fight the appearances of puffiness, dark circles and crow's feet. The diligent formulation contains Hyaluronic Acid, D-Panthenol and a complex of Ash tree bark extract, organic silicon and Vitamin B3 for radiant, glowing skin and a fresher look.
Perfume free. 30 ml.
-
farewell dry skin: farewell dry skin contains hydrating ingredients including Hyaluronic Acid, Niacinamide, D-Panthenol and Aloe Vera to effectively nourish the skin and strengthen the skin barrier. Softens the skin and boosts elasticity.
Perfume free. 30 ml.
-
farewell aging skin: farewell aging skin is enriched with Hyaluronic Acid, Madecassoside, Vitamin C, Marine ferment extract and a plant-derived Retinol alternative to hydrate the skin and improve suppleness and firmness while effectively reducing the signs of aging.
Perfume free. 30 ml.
-
farewell oily skin: Formulated especially for oily and acne-prone skin, farewell oily skin contains a zinc complex and plankton extract to reduce blemishes and clogged pores, while diminishing the facial sebum production. Niacinamide and Wintergreen leaf extract regenerate the skin barrier for a softer skin and a glowing complexion.
Perfume free. 30 ml.
farewell follows clean beauty concept
More and more people attach great importance to responsible consumption. Croma farewell™ complies with this wish – all serums are vegan, free from silicones, perfumes, mineral oils and are developed and produced exclusively in Austria. The products are cruelty-free and contain no animal-derived ingredients.
Price and availability
The Croma farewell™ facial serums are available soon via the Croma skincare web shop www.cromaskincareshop.com
and selected partners.
Recommended retail price: EUR 119,-.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210531005179/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“Moutai Night” Makes Seoul Debut, Celebrating China–South Korea Cultural Exchange3.11.2026 14:17:00 CET | Press release
On October 25, the 2026 “Moutai Night” was held in Seoul, South Korea, under the theme “Born by the Chishui River, Fragrance Along the Han River.” Over a hundred guests from China and South Korea gathered around the Han River, sharing the distinctive appeal of Chinese baijiu, and fostering cultural exchange between the two countries through fine liquor and culture. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103333206/en/ “Moutai Night” Makes Seoul Debut, Celebrating China–South Korea Cultural Exchange The event featured an exhibition on Moutai’s brewing techniques and brand history. Hands-on experiences with Miao batik and silverwork showcased Guizhou culture, while creative cocktails brought Chinese spirits into dialogue with Korean tastes. A city-themed video, dance performances and a violin performance rounded out the program, as guests exchanged views on liquor culture in a warm atmosphere. As a flagship cultural
TVS Motor Company Strengthens Its European Presence With Four Production-Ready Models at EICMA 20263.11.2026 14:14:00 CET | Press release
TVS Motor expands its European presence through dedicated engineering facilities, a strengthened retail network and products developed for local customer needs Four production-ready models broaden the company's offering across electric mobility, premium urban transportation and lightweight sports motorcycling Global manufacturing scale, technology expertise and international engineering capabilities provide the foundation for TVS Motor's long-term success in Europe TVS Motor Company, the world's third-largest two-wheeler manufacturer, today unveiled four production-ready models at EICMA 2026 in Milan, reinforcing its commitment to Europe as a strategic market. The showcase highlights products developed for European customers, supported by dedicated engineering capabilities, an expanding retail network, and the strengths of TVS Motor's global manufacturing, technology and product development ecosystem. This press release features multimedia. View the full release here: https://www.busin
Teamily AI Reports 32× Quarterly User Growth, Positive Gross Margins, and Strong Global Adoption of Human–Agent Collaboration3.11.2026 14:00:00 CET | Press release
The AI-native collaboration platform reaches 320,000 users across 100+ countries, validates product-led growth and monetization, and prepares to expand its global AI agent ecosystem. Teamily AI, a human–agent collaboration platform that enables people and AI agents to work together in a unified, context-aware workspace, today announced significant growth and commercial milestones following a quarter of rapid global expansion. The company grew from 10,000 to 320,000 sign-ups in a single quarter, a 32× increase that works out to a compound monthly growth rate of 217.5%, just three months after its public launch in July 2026. With positive gross margins on paying users, and growing adoption among professional teams and businesses, Teamily AI establishes a foundation for scalable product-led growth (PLG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103047955/en/ 32× Global Growth in One Quarter Teamily AI grew from 10,000
Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 13:40:00 CET | Press release
One provider for identity, compliance and fraud prevention across 50+ countries, with a single integrated platform. Fourthline and Veridas combined will create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US; on track for 200 million verifications in 2026. With a projected combined revenue of more than €50m in 2026 and both businesses EBITDA-positive at closing, the company expects to reach €85m annual recurring revenue in 2029. Financials: The transaction includes funding of up to €65m provided by existing shareholder Finch Capital, new equity investment from Seaya Andromeda and debt financing from Ashgrove Capital. Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full rele
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release
Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom